Baffler
09 Nov 2016
Trading up due? Trading update last year was on 17th of November
Baffler
02 Nov 2016
Re: BENCARD IN THE NEWS AGAIN! Sir,Am I alone in noting that Manuel slipped the word Influenza in front of Malaria to-day.?What are the odds of the next RNS in relation to Bencard not being a non RNS?Shortening I would say !IMPO/DYOR.
Baffler
02 Nov 2016
BENCARD IN THE NEWS AGAIN! 2 November 2016 Allergy Therapeutics plc ("Allergy Therapeutics" or the "Company"
European Patent Office grants new and expanded patent underpinning Allergy Therapeutics' core Microcrystalline Tyrosine technology Patent already granted in the United Kingdom and New Zealand Allergy Therapeutics (AIM:AGY), the fully integrated pharmaceutical company specialising in allergy vaccines, today announces that the European Patent Office has granted a broad technology patent relating to the Company's unique Microcrystalline Tyrosine (MCT) depot adjuvant manufacturing process. This patent covers the novel manufacture and physiochemical characteristics of MCT in combination with one or more antigens, further strengthening the Company's core intellectual property. The granting of this patent further strengthens Bencard Adjuvant Systems, the wholly-owned division of Allergy Therapeutics which specialises in developing and optimising aluminium-free adjuvants for infectious diseases. Recent data generated have shown how MCT has a synergistic effect when coupled with another adjuvant from BAS's portfolio, Virus Like Particles (VLP), to create the adjuvant system AdSys-VcT. As recently announced, this adjuvant system demonstrated protective efficacy in a malaria model in a study performed in collaboration with the University of Oxford, UK. Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: "We are pleased to expand this key patent and are excited by the potential for MCT as a core technology within our adjuvant portfolio to create novel and efficacious vaccines, both in allergies and also in infectious disease areas such as malaria and influenza. This further underpins the future pipeline for products, and the long term success of Allergy Therapeutics to continue innovating and producing novel medicines."
Maddoxx
18 Oct 2016
The Bencard opportunity The significance of the Bencard news, and the opportunity in malaria inoculation, is that it suggests that their Adjuvant might have even wider applicability beyond these areas. Think of the potential implications....Hypothetically, if Allergy's adjuvant can make other vaccines more effective then that can be a new patent and will extend the life of a Pharma Co's existing product. The value proposition will be pretty evident to the vaccine owner that would, I suggest, have to fund the improved formula through the approval process. Allergy would only need to license their adjuvant to the Pharma for its specific use.Regards, Maddox
II Editor
17 Oct 2016
NEW ARTICLE: Share of the week: Tipped to double again "In a week when the FTSE 100 finally made an all-time high there were surprisingly few big winners among either the large or mid-caps. A three-day losing streak for the blue-chip index clearly took some froth out of the market, which is why we ..."[link]
II Editor
14 Oct 2016
NEW ARTICLE: Share of the week: Tipped to double again "In a week when the FTSE 100 finally made an all-time high there were surprisingly few big winners among either the large or mid-caps. A three-day losing streak for the blue-chip index clearly took some froth out of the market, which is why we ..."[link]
Baffler
14 Oct 2016
Re: A growing market? Hi DaveI met with Manuel last week and mentioned that I go back to MDY days. It was before his time.Charles Spicer was quite visionary on many of his selections and he was the prime reason that I bought into here.This is now a class business with a wide range of exciting opportunities along with a proven track record in growing a market leading position and buying the right businesses and making them work. It is worth looking at the board and management team.The Bencard news was especially interesting. Is it watch this space?There appears to be a solid news flow over the coming months and lord knows where we may end up.Me? I am in for the ride and still buying.Good LuckJim
d gaser
14 Oct 2016
Re: A growing market? Its been a long journey don't you think Baffler .I can't remember how many times we have thought this company would come up with the goods but at long last it appears those buys all those years ago will now come good . I can Remember this being tipped by M.D.Y all those years ago,.now I hope, A.G.Y can produce the returns we both expected from this company ,and hopefully this is just the start of a very good year to come.BE HAPPYDav
Chicken Lips
13 Oct 2016
Re: Bencard - Very impressive indeed! Thanks Buffer
Baffler
13 Oct 2016
Bencard - Very impressive indeed! [link]
Baffler
12 Oct 2016
A growing market? [link]
Chicken Lips
10 Oct 2016
Re: Bencard news Thanks BafflerNews seems to have gone down well. Bought a small number on back of this.
Baffler
10 Oct 2016
Re: Bencard news CLi doubt if they can as it is subscription @£40.00 pmBehind the scenes we appear to be getting a lot of encouraging coverage all are saying BUY.dyor/impoThis mornings news was something very interesting to be. It required two or three readings.jl
Chicken Lips
10 Oct 2016
Re: Bencard news HiCould you paste the full article? That would be great.ThanksPeter
Baffler
10 Oct 2016
Bencard news This mornings RNS came from 'left of field' for me but is really interesting to see the width of AGY. Allergy Therapeutics presents enhanced efficacy data in a malaria vaccine model with its novel adjuvant system. Data to be presented today at the World Vaccine Congress demonstrates "significant improvements" in effective infectious disease applications using Bencard Adjuvant Systems technology. dyor/impo
